v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Revenues $ 5,428 $ 6,195 $ 15,974 $ 16,953
Cost of revenues [1] 3,941 3,488 10,436 9,613
Gross profit 1,487 2,707 5,538 7,340
Operating expenses:        
Research and development, net 1,941 721 9,540 2,406
Sales and marketing 3,351 3,168 10,153 10,790
General and administrative [2] 2,165 1,958 6,306 5,917
Impairment charges 0 0 0 2,783
Total operating expenses 7,457 5,847 25,999 21,896
Operating loss (5,970) (3,140) (20,461) (14,556)
Financial expense (income), net [3] (926) 23 6,879 (8)
Loss before income taxes (5,044) (3,163) (27,340) (14,548)
Taxes on income 8 7 24 18
Net loss $ (5,052) $ (3,170) $ (27,364) $ (14,566)
Net loss per ordinary share, basic $ (1.32) $ (2.37) $ (9.91) $ (13.87)
Net loss per ordinary share, diluted $ (1.32) $ (2.37) $ (9.91) $ (13.87)
Weighted average number of shares used in computing net loss per ordinary share, basic [4] 3,836,950 1,335,117 2,760,466 1,050,290
Weighted average number of shares used in computing net loss per ordinary share, diluted [4] 3,836,950 1,335,117 2,760,466 1,050,290
[1] Includes revenue sharing expense attributable to Oramed Pharmaceuticals Inc., a related party, of $66 thousand and $168 thousand for the three and nine months ended September 30, 2026, respectively. See Note 10.
[2] Includes legal expense attributable to Oramed Pharmaceuticals Inc., a related party, of $67 thousand for the three and nine months ended September 30, 2026. See Note 10.
[3] Includes net financing expense attributable to Oramed Pharmaceuticals Inc., a related party, consisting of interest expense and changes in the fair value of warrant and derivative liabilities, of $405 thousand and $7,875 thousand for the three and nine months ended September 30, 2026, respectively. See Note 9.
[4] Reflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a.